Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3-4
|
| pubmed:dateCreated |
1988-1-19
|
| pubmed:abstractText |
Indomethacin was administered subcutaneously to rats, 4 mg/kg/day for 4 consecutive days in order to produce erosions of the small intestine which were scored at necropsy on day 5. Orally administered phenidone (up to 250 mg/kg/day), a mixed cycloocygenase-lipoxygenase inhibitor, failed to produce intestinal erosions, but tended to exacerbate indomethacin-induced erosions. A 5-LO inhibitor, diphenyldisulfide, provided significant protection at 10-100 mg/kg when given orally to indomethacin-treated rats. Sulfasalazine, auranofin and cyproheptadine, but not cimetidine, also protected, suggesting a role for mast cell activation and leukotriene generation in indomethacin-induced ulcerogenesis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0065-4299
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
21
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
314-5
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:3687586-Animals,
pubmed-meshheading:3687586-Disulfides,
pubmed-meshheading:3687586-Indomethacin,
pubmed-meshheading:3687586-Intestinal Diseases,
pubmed-meshheading:3687586-Lipoxygenase Inhibitors,
pubmed-meshheading:3687586-Male,
pubmed-meshheading:3687586-Rats,
pubmed-meshheading:3687586-Ulcer
|
| pubmed:year |
1987
|
| pubmed:articleTitle |
Diphenyldisulfide inhibits indomethacin-induced ulcerogenesis in rats.
|
| pubmed:affiliation |
Institute of Biological Sciences, Syntex Research, Palo Alto, CA 94304.
|
| pubmed:publicationType |
Journal Article
|